Today: 17 June 2026
Browse Category

Pharmaceutical Industry 28 February 2026 - 10 June 2026

Why AIM ImmunoTech Stock More Than Doubled Today After a Pancreatic Cancer Trial Surprise

Why AIM ImmunoTech Stock More Than Doubled Today After a Pancreatic Cancer Trial Surprise

AIM ImmunoTech shares soared over 100% to 92.79 cents on record volume after its pancreatic-cancer trial hit final subject enrollment ahead of schedule. The last patient is set for mid-June treatment, with the main Ampligen efficacy readout due in December. AIM recently raised $2.4 million in a discounted share offering, adding dilution risk. Monday’s rally came as biotech peers fell, highlighting stock-specific momentum.
1 June 2026
··
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
17 May 2026
··
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen has closed its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and delisting its shares from Nasdaq. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains the drugs Empaveli and Syfovre, and expands into kidney disease. Biogen borrowed $2 billion to help finance the deal.
15 May 2026
···
Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics priced a $375 million public offering after reporting positive Phase 2 results for abdakibart in hidradenitis suppurativa. The company will sell 19.73 million shares at $17.75 each and pre-funded warrants for 1.4 million shares. Shares rose 34% to $21.73 by midday. The Phase 2 trial showed HiSCR75 response rates of over 42% for both dosing regimens versus 25.6% for placebo.
6 May 2026
··
Esperion Stock Surges On ARCHIMED’s $1.1 Billion Buyout — What Shareholders Get Next

Esperion Stock Surges On ARCHIMED’s $1.1 Billion Buyout — What Shareholders Get Next

ARCHIMED will acquire Esperion Therapeutics for $3.16 per share in cash plus a contingent value right tied to future sales, valuing the deal at up to $1.1 billion. Esperion shares surged 56% to near the cash offer after the announcement. The CVR could pay up to $100 million if sales targets are met. The deal follows Esperion’s recent expansion beyond cholesterol drugs.
1 May 2026
·
Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics reported its experimental psoriasis drug ORKA-001 achieved complete skin clearance in 63.5% of patients at 16 weeks. Shares jumped 10.5% to $76.39 before the company launched a $500 million public offering. No serious adverse events were reported in the trial. ORKA-001 is being developed as a long-acting injectable, with annual dosing possible.
27 April 2026
···
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
18 April 2026
··
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides, removing 12 from a high-risk list and scheduling a July review of seven more. The move follows Hims’ March decision to stop advertising compounded GLP-1 drugs and expand branded offerings through Novo Nordisk. The company acquired a California peptide facility last year to bolster supply.
16 April 2026
···
ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio shares fell 21.1% Tuesday after the FDA posted a warning letter accusing the company of false or misleading claims about its cancer drug Anktiva in a TV ad and podcast. The FDA said the materials suggested Anktiva could cure or prevent all cancer, which is not approved. ImmunityBio has 15 working days to respond. Anktiva accounted for nearly all of the company’s $113 million in 2025 revenue.
25 March 2026
··
Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics shares jumped 18% Monday after reports that FDA biologics chief Vinay Prasad will depart in April. The move follows the agency’s January rejection of Atara’s EBVALLO therapy for a rare blood cancer, which wiped out 56% of the stock’s value. Atara and partner Pierre Fabre have requested a Type A meeting with the FDA to revisit the decision. Atara ended 2025 with $8.5 million in cash.
9 March 2026
····
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Capricor Therapeutics shares jumped 7.6% to $30.01 after the company set March 12 for its quarterly and annual update, spotlighting its Duchenne muscular dystrophy therapy, deramiocel. An MDA conference abstract showed deramiocel met main goals in a 106-patient Phase 3 trial, with no imbalance in severe adverse events. The FDA rejected approval in July but later requested the full study report.
9 March 2026
·
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Day One Biopharmaceuticals shares traded at $21.24 Monday, just below Servier’s $21.50-per-share cash offer in a $2.5 billion takeover. The deal would give Servier Ojemda, the only U.S.-approved single-drug treatment for pediatric low-grade glioma, with 2025 sales of $155.4 million. The tender offer has not started and closing depends on shareholder response and U.S. antitrust clearance.
9 March 2026
Tango Therapeutics stock jumps 36% after Q4 results, Erasca cancer trial pact

Tango Therapeutics stock jumps 36% after Q4 results, Erasca cancer trial pact

Tango Therapeutics shares rose 36% after announcing a collaboration with Erasca to test vopimetostat in pancreatic and lung cancers. The company reported a fourth-quarter net loss of $38.7 million and cash reserves of $343.1 million. Tango plans to start a pivotal pancreatic cancer trial in 2026 and released early efficacy data from ongoing studies.
6 March 2026
···
1 2 3 … 9

Stock Market Today

  • ERock Simplifies Equity Structure and Adds Independent Board After IPO
    June 16, 2026, 9:15 PM EDT. ERock (NYSE:EROC) completed its IPO, raising capital to support its power systems business. The company simplified its equity structure through repurchases and restructuring, adopting new bylaws and a revised certificate of incorporation. It established a new independent board with defined committee roles, aiming to strengthen governance. ERock trades at $15.30 with no analyst price targets yet and is flagged as undervalued by one estimate, trading nearly 96% below fair value. Investors should monitor how the board manages IPO proceeds against current revenue of $190.8 million and a net loss of $68.2 million. Shares are highly illiquid, possibly causing wider spreads and price volatility. These changes offer a clearer foundation for public oversight as ERock transitions to a public company.

Latest articles

Dow Closes at Record in After-Hours as S&P 500, Nasdaq Dip on Tech Slide

Dow Closes at Record in After-Hours as S&P 500, Nasdaq Dip on Tech Slide

17 June 2026
Dow hits second straight record close at 51,999.67 while S&P 500 and Nasdaq drop as tech stocks slide; Philadelphia semiconductor index plunges 5.7% and after-hours trading sees only slight gains for major index-tracking funds, as investors brace for Wednesday’s Fed decision and monitor inflation risks amid falling oil prices and a possible U.S.-Iran deal.
GD Culture shares drop on heavy trading and ongoing buyout uncertainty

GD Culture shares drop on heavy trading and ongoing buyout uncertainty

17 June 2026
GD Culture Group plunged 73.3% to $0.028 after heavy trading, putting fresh pressure on its unresolved, non-binding $10.75-per-share buyout proposal; risks include deal uncertainty, a $300 million share-sale program, and bitcoin-driven balance sheet swings, with no new company updates released Tuesday.
Go toTop